Official Positions for FRAX® Clinical Regarding Rheumatoid Arthritis

被引:32
|
作者
Broy, Susan B. [1 ]
Tanner, S. Bobo [2 ]
机构
[1] Chicago Med Sch, Rosalind Franklin Sch Med, N Chicago, IL USA
[2] Vanderbilt Univ, Med Ctr, Div Rheumatol & Allergy, Nashville, TN USA
基金
英国医学研究理事会;
关键词
Rheumatoid arthritis; osteoporosis; osteoporotic fracture; vertebral fracture; fracture risk; FRAX; BONE-MINERAL DENSITY; VERTEBRAL DEFORMITIES; RISK-FACTORS; FRACTURE RISK; INFLAMMATORY MARKERS; JAPANESE WOMEN; HIP-FRACTURES; OSTEOPOROSIS; ASSOCIATIONS; VARIABLES;
D O I
10.1016/j.jocd.2011.05.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rheumatoid arthritis is the only secondary cause of osteoporosis that is considered independent of bone density in the FRAX (R) algorithm. Although input for rheumatoid arthritis in FRAX (R) is a dichotomous variable, intuitively, one would expect that more severe or active disease would be associated with a greater risk for fracture. We reviewed the literature to determine if specific disease parameters or medication use could be used to better characterize fracture risk in individuals with rheumatoid arthritis. Although many studies document a correlation between various parameters of disease activity or severity and decreased bone density, fewer have associated these variables with fracture risk. We reviewed these studies in detail and concluded that disability measures such as HAQ (Health Assessment Questionnaire) and functional class do correlate with clinical fractures but not morphometric vertebral fractures. One large study found a strong correlation with duration of disease and fracture risk but additional studies are needed to confirm this. There was little evidence to correlate other measures of disease such as DAS (disease activity score), VAS (visual analogue scale), acute phase reactants, use of non-glucocorticoid medications and increased fracture risk. We concluded that FRAX (R) calculations may underestimate fracture probability in patients with impaired functional status from rheumatoid arthritis but that this could not be quantified at this time. At this time, other disease measures cannot be used for fracture prediction. However only a few, mostly small studies addressed other disease parameters and further research is needed. Additional questions for future research are suggested.
引用
收藏
页码:184 / 189
页数:6
相关论文
共 50 条
  • [1] Official Positions for FRAX® Clinical Regarding Smoking
    Dimai, Hans P.
    Chandran, Manju
    JOURNAL OF CLINICAL DENSITOMETRY, 2011, 14 (03) : 190 - 193
  • [2] Official Positions for FRAX® Clinical Regarding Prior Fractures
    Blank, Robert D.
    JOURNAL OF CLINICAL DENSITOMETRY, 2011, 14 (03) : 205 - 211
  • [3] Official Positions for FRAX® Clinical Regarding Biochemical Markers
    McCloskey, Eugene V.
    Vasikaran, Samuel
    Cooper, Cyrus
    JOURNAL OF CLINICAL DENSITOMETRY, 2011, 14 (03) : 220 - 222
  • [4] Official Positions for FRAX® Clinical Regarding International Differences
    Cauley, Jane A.
    El-Hajj Fuleihan, Ghada
    Arabi, Asma
    Fujiwara, Saeko
    Ragi-Eis, Sergio
    Calderon, Andrew
    Chionh, Siok Bee
    Chen, Zhao
    Curtis, Jeffrey R.
    Danielson, Michelle E.
    Hanley, David A.
    Kroger, Heikki
    Kung, Annie W. C.
    Lesnyak, Olga
    Nieves, Jeri
    Pluskiewicz, Wojciech
    El Rassi, Rola
    Silverman, Stuart
    Schott, Anne-Marie
    Rizzoli, Rene
    Luckey, Marjorie
    JOURNAL OF CLINICAL DENSITOMETRY, 2011, 14 (03) : 240 - 262
  • [5] Official Positions for FRAX® Clinical Regarding Falls and Frailty: Can Falls and Frailty be Used in FRAX®?
    Masud, Tahir
    Binkley, Neil
    Boonen, Steven
    Hannan, Marian T.
    JOURNAL OF CLINICAL DENSITOMETRY, 2011, 14 (03) : 194 - 204
  • [6] Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture
    Leib, Edward S.
    Saag, Kenneth G.
    Adachi, Jonathan D.
    Geusens, Piet P.
    Binkley, Neil
    McCloskey, Eugene V.
    Hans, Didier B.
    JOURNAL OF CLINICAL DENSITOMETRY, 2011, 14 (03) : 212 - 219
  • [7] Official Positions for FRAX® Bone Mineral Density and FRAX® Simplification
    Lewiecki, E. Michael
    Compston, Juliet E.
    Miller, Paul D.
    Adachi, Jonathan D.
    Adams, Judith E.
    Leslie, William D.
    Kanis, John A.
    Moayyeri, Alireza
    Adler, Robert A.
    Hans, Didier B.
    Kendler, David L.
    Diez-Perez, Adolfo
    Krieg, Marc-Antoine
    Masri, Basel K.
    Lorenc, Roman R.
    Bauer, Douglas C.
    Blake, Glen M.
    Josse, Robert G.
    Clark, Patricia
    Khan, Aliya A.
    JOURNAL OF CLINICAL DENSITOMETRY, 2011, 14 (03) : 226 - 236
  • [8] Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®
    Hans, Didier B.
    Kanis, John A.
    Baim, Sanford
    Bilezikian, John P.
    Binkley, Neil
    Cauley, Jane A.
    Compston, Juliet E.
    Cooper, Cyrus
    Dawson-Hughes, Bess
    El-Hajj Fuleihan, Ghada
    Leslie, William D.
    Lewiecki, E. Michael
    Luckey, Marjorie M.
    McCloskey, Eugene V.
    Papapoulos, Socrates E.
    Poiana, Catalina
    Rizzoli, Rene
    JOURNAL OF CLINICAL DENSITOMETRY, 2011, 14 (03) : 171 - 180
  • [9] The application of the FRAX tool in rheumatoid arthritis patients
    Burns, J.
    Bradley, C.
    McClelland, V.
    Finch, M. B.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2010, 179 : S553 - S553
  • [10] FRAX AND DAS IN MOROCCAN RHEUMATOID ARTHRITIS PATIENTS
    Azzouzi, H.
    Lamkhanat, O.
    Linda, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 971 - 971